V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

Why start-ups can become mega companies in the pharma sector

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully […] November 20, 2018 · V-Bio Ventures

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) – V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals Camel-IDS […] November 15, 2018 · V-Bio Ventures

Are tech investments under threat by anti-science sentiments?

In biotech, company creation is usually preceded by scientific discoveries presenting solutions to existing problems. Because of this, early stage […] October 30, 2018 · V-Bio Ventures

Bringing clinical trials into the home

Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions […] October 2, 2018 · V-Bio Ventures

V-Bio Ventures participates in 22.5 million euros series B financing round of Horama

Ghent (Belgium), September 18th, 2018 – The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins […] September 18, 2018 · V-Bio Ventures

Forever young: the science of aging well

“Is aging a disease?” For a long time, the answer to this question seemed obvious: aging is a natural thing […] August 28, 2018 · V-Bio Ventures

Biotechs and subsidies - a fraught relationship

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. […] July 23, 2018 · V-Bio Ventures

Acquisitions of Biotech companies: a good or a bad thing?

When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only […] May 14, 2018 · V-Bio Ventures

How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world. Only […] April 19, 2018 · V-Bio Ventures

Is innovation killing the pharmaceutical industry?

In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly […] March 18, 2018 · V-Bio Ventures

Artificial intelligence beyond the hype: achievements and expectations in the biotech space

Artificial intelligence (AI) is a term that pops up everywhere lately. In this article, we provide some examples of how […] January 18, 2018 · V-Bio Ventures

New cures for hereditary diseases around the corner?

Hereditary diseases are caused by mutations or deletions in (single) genes that lead to either dysfunctional or inadequate levels of […] December 18, 2017 · V-Bio Ventures

Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when […] November 20, 2017 · V-Bio Ventures

How Aphea.Bio managed to gather the funds to transcend from academia to industry

Aphea.Bio is an agriculture startup, originating from the VIB and flourishing underneath the wings of V-Bio Ventures. Steven Vandenabeele (CTO […] October 16, 2017 · V-Bio Ventures

The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects […] September 11, 2017 · V-Bio Ventures